An interventional study of Inspire Upper Airway Stimulation (UAS) System in Down Syndrome and Obstructive Sleep Apnea, sponsored by Inspire Medical Systems, Inc.. Active, not recruiting at 8 sites in United States. Open to participants aged 10 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Inspire Medical Systems, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Down Syndrome with a site in United States — 47 open to participants now, 55 under way, 4 of them phase 3. Down Syndrome · United States.
Among the 205 studies in Down Syndrome with a site in United States, this one is the 47th largest by enrollment of the 131 interventional ones that give a count, is one of 16 that started in 2021, is one of 82 with no phase, reaches primary completion later than 5 of the 54 other live ones, and was the 136th registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →47 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Spain, United Kingdom
Ages 40–55
Ohio State University · Sites in United States
Ages 5–12
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 6–22
RTI International · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 10 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 26 · Phase 3 10 · Phase 4 5
First in 1981; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 38 across 287 interventional studies indexed under Down Syndrome.
Median enrollment 40 across the 131 interventional studies, 433 across the 74 observational. Of the 140 that completed or were terminated, 42 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 205 have an industry lead sponsor. The 10 most frequent:
Inspire Medical Systems, Inc. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Inspire Medical Systems, Inc. has 2 studies filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
14 of the studies in Down Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07008989Boston CollegeA VIRTUAL Three-month Intervention Study of the Effects of a Smartphone Application (HippoCamera) on Memory in Teens and Young Adults With Down Syndrome | 2026-12-31 |
| NCT05196984Massachusetts Institute of TechnologyGamma Frequency Stimulation in Individuals With Down Syndrome | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 205 studies in Down Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
Prior to implant subjects will be required to meet eligibility criteria, complete quality of life questionnaires and undergo neurocognitive testing (NCT) and expressive language sampling. Eligibility criteria will be determined via review of medical records, an in-lab polysomnography (sleep study), and a drug-induced sleep endoscopy (DISE).
After implant of the Inspire UAS System, subjects will undergo five (5) study visits. Four (4) of the visits will include an in-lab sleep study (PSG). Follow-up expressive language sampling and neurocognitive testing will be performed at 6 months post-implant. Follow-up quality of life questionnaires will be completed at 12 months post-implant.
Subjects will conclude their participation in the study at the end of their 12 month study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
Device: Inspire Upper Airway Stimulation (UAS) System
The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
Also known as: Hypoglossal nerve stimulation
Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2)
Change in the Intelligence Quotient Standard Score of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Change in attention using the Wechsler Intelligence Scale
Change in Cancellation scaled score of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Change in processing speed using the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Change in RTIFMDRT and RTIFMDMT raw scores of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Change in executive functioning using the Delis-Kaplan Executive Functioning System (DKEFS)
Change in Category Functioning scaled score of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Change in learning and memory using the Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning
Change in PAL-TEA raw score of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Change in language using Expressive Language Sampling
Change in % of unintelligible C-units, number of different word roots and mean length of C-units in morphemes of at least 0.5 standard deviation from baseline
Time frame: 6 Months post-implant
Rate of procedure and device-related adverse events
Procedure and device-related adverse events will be collected in order to profile the safety of hypoglossal nerve stimulation in adolescents. Number and percent of procedure and device-related adverse events will be reported
Time frame: Implant through 12 Months post-implant
Change in Obstructive Sleep Apnea (OSA)
Change in sleep apnea will be measured using standard in-lab PSG measures including oxygen level, partial and complete airway obstruction, and arousals. Improvement will be defined as a 50% or more decrease in AHI.
Time frame: 3, 6, 12 Months post-implant
Change in quality of life as measured by OSA-18 and ESS-CHAD questionnaires
Quality of life improvements will be measured using the OSA-18 and ESS-CHAD. Mean scores for each questionnaire will be reported at baseline and 12 months post-implant.
Time frame: 12 months post-implant
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Jul 2026, 60 months.
Of 165 interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inspire Medical Systems, Inc.